Clinical Trial: Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell Carcinoma: A Randomized Controlled Trial

U.S., April 18 -- ClinicalTrials.gov registry received information related to the study (NCT07535567) titled 'Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell Carcinoma: A Randomized Controlled Trial' on April 10.

Brief Summary: A Multicenter, Randomized, Controlled, Open-Label, Phase II/III Clinical Trial to evaluate the efficacy and safety of postoperative radiotherapy and Nimotuzumab with/without Bemcentinib in intermediate-risk pathological patients with head and neck squamous cell carcinoma.The primary endpoint is 3-year disease-free survival (DFS). A total of 193 patients will be enrolled in both the study group and the control group, respectively, with a total planned ...